<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305821</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_30046_ISTCAT</org_study_id>
    <nct_id>NCT04305821</nct_id>
  </id_info>
  <brief_title>Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics</brief_title>
  <acronym>ISTCAT</acronym>
  <official_title>Intérêt de la protéine S100β Dans Les Traumatismes Crâniens légers Sous Anti-Thrombotiques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Head trauma is a common injury in emergency department. Investigation to search for
      complication is guided by the clinical examination and the case history, such as taking
      anti-thrombotics. Cranial computed tomography (CCT) is the gold standard to investigate, and
      is mandatory in case of antithrombotic drugs.

      Recently, some biomarkers have proven their utility to rule-out mild head trauma without CCT
      in the general population. Among these biomarkers, S100β protein has been added in guidelines
      for mild head trauma. Some studies have found similar data in population taking anticoagulant
      or antiplatelet drugs.

      The investigators aim to prove medical utility of S100β protein in population under
      antithrombotics, by the reduction of CCT use. Then, The investigators hypothesize that the
      add of S100β protein reduces cost of health care in the management of head injury in that
      population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">March 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performances are evaluated by AUC</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performances are evaluated by sensibility, specificity</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performances of S100β protein in case of mild head trauma for detection of traumatic intracranial lesion in patients under antithrombotic medication compare to cranial computed tomography.</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic performances are evaluated by positive and negative predictive values between the strategy with S100β protein compared to the strategy with systematic cranial computed tomography.</description>
  </primary_outcome>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Mild Head Injury</condition>
  <condition>Anticoagulant</condition>
  <condition>Antiplatelet</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of S100β protein</intervention_name>
    <description>Dosage of S100β protein</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient taking antithrombotic medication with mild head trauma and trauma occured ≤ 6 hours
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥ 18 years old

          -  Taking antithrombotic medication (antiplatelet drugs, K vitamin antagonist, direct
             oral anticoagulants, heparins)

          -  Mild head trauma with Glasgow coma scale ≥ 13

          -  Trauma occured ≤ 6 hours

          -  Agreeing the participation in the study

        Exclusion Criteria:

          -  Head injury occured &gt; 6 hours

          -  Patient &lt; 18 years old or under juridic protection

          -  pregnant women

          -  polytrauma

          -  Glasgow coma scale ≤ 12

          -  ancient or actual cerebral ou cutaneous neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Cédric GANGLOFF, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Univesitaire de Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristell COAT</last_name>
    <phone>299282555</phone>
    <phone_ext>+33</phone_ext>
    <email>kristell.coat@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Direction de la recherche</last_name>
    <phone>2 99 28 25 25</phone>
    <phone_ext>+33</phone_ext>
    <email>dri@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Quilcaille</last_name>
      <email>Xavier.QUILCAILLE@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric GANGLOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild head injury, traumatic brain injury, traumatic intracranial hemorrhage</keyword>
  <keyword>Anticoagulant, antiplatelet, anticoagulant, antithrombotic</keyword>
  <keyword>S100β protein</keyword>
  <keyword>health care cost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

